Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • mRNA immunotherapy

    - PMLiVE

    NHS programme to give head and neck cancer patients fast-track access to mRNA vaccine

    More than 11,000 people are diagnosed with head and neck cancers every year in England

    - PMLiVE

    BioNTech expands mRNA capabilities with $1.25bn CureVac acquisition

    The deal will support the advancement of BioNTech’s mRNA-based cancer immunotherapies

    - PMLiVE

    BMS and BioNTech partner on solid tumour candidate in deal worth over $11bn

    BioNTech’s BNT327 is being evaluated in multiple clinical trials, including phase 3 studies in first-line lung cancer

    - PMLiVE

    BioNTech announces £1bn UK investment to boost regional R&D presence

    The UK government has also agreed to award the company a grant of up to £129m

    - PMLiVE

    NHS programme to give melanoma patients fast-track access to skin cancer vaccine

    The phase 2 study will evaluate Scancell's iSCIB1+ in patients with advanced unresectable melanoma

    - PMLiVE

    British Skin Foundation receives £10,000 donation from Circle Health Group

    The healthcare provider’s previous donation is supporting research into early melanoma detection

    - PMLiVE

    Pfizer/BioNTech’s KP.2-adapted COVID-19 vaccine receives CHMP recommendation

    The updated vaccine was shown to generate an improved response against currently circulating variants

    - PMLiVE

    Merck shares positive ten-year results for Keytruda in advanced melanoma

    More than 100,640 cases of the skin cancer are expected to be diagnosed in the US this year

    - PMLiVE

    FDA approves updated COVID-19 vaccines to better protect against current variants

    Adapted vaccines from Pfizer/BioNTech and Moderna have been authorised for individuals aged six months and older

    - PMLiVE

    Pfizer and BioNTech share late-stage results for COVID-19/flu combination vaccine

    The combined vaccine approach could simplify immunisation practices and lead to higher uptake

    - PMLiVE

    BioNTech shares promising results for mRNA immunotherapy candidate in advanced melanoma

    Melanoma is currently responsible for around 58,000 deaths globally every year

    - PMLiVE

    Pfizer/BioNTech’s Omicron JN.1-adapted COVID-19 vaccine recommended by CHMP

    The vaccine generated an improved response against several Omicron JN.1 sublineages

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links